{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:56:27Z","timestamp":1781164587547,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015691","name":"NIAID DMID","doi-asserted-by":"publisher","award":["HHS-N272201400053C"],"award-info":[{"award-number":["HHS-N272201400053C"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.vaccine.2023.08.009","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T16:01:32Z","timestamp":1691596892000},"page":"5730-5741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-8621","authenticated-orcid":false,"given":"Yoshikazu","family":"Honda-Okubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bart Tarbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L.","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-5245","authenticated-orcid":false,"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.08.009_b0005","doi-asserted-by":"crossref","first-page":"2155072","DOI":"10.1080\/22221751.2022.2155072","article-title":"Alarming situation of emerging H5 and H7 avian influenza and effective control strategies","volume":"12","author":"Shi","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2023.08.009_b0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/CMR.00037-06","article-title":"Avian influenza virus (H5N1): a threat to human health","volume":"20","author":"Peiris","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2023.08.009_b0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038620","article-title":"The epidemiology, virology, and pathogenicity of human infections with avian influenza viruses","volume":"11","author":"Wang","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2023.08.009_b0020","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3201\/eid1309.070111","article-title":"Detecting human-to-human transmission of avian influenza A (H5N1)","volume":"13","author":"Yang","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.009_b0025","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1038\/emi.2013.89","article-title":"Receptor binding and transmission studies of H5N1 influenza virus in mammals","volume":"2","author":"Zhao","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2023.08.009_b0030","doi-asserted-by":"crossref","DOI":"10.1093\/molbev\/msad019","article-title":"Bidirectional movement of emerging H5N8 avian influenza viruses between Europe and Asia via migratory birds since early 2020","volume":"40","author":"Zhang","year":"2023","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.vaccine.2023.08.009_b0035","doi-asserted-by":"crossref","first-page":"e13038","DOI":"10.7717\/peerj.13038","article-title":"Highly pathogenic avian influenza virus of the A\/H5N8 subtype, clade 2.3.4.4b, caused outbreaks in Kazakhstan in 2020","volume":"10","author":"Amirgazin","year":"2022","journal-title":"PeerJ"},{"key":"10.1016\/j.vaccine.2023.08.009_b0040","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.24.2100439","article-title":"Isolation of clade 2.3.4.4b A(H5N8), a highly pathogenic avian influenza virus, from a worker during an outbreak on a poultry farm, Russia, December 2020","volume":"26","author":"Pyankova","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2023.08.009_b0045","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.08.009_b0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4161\/hv.2.1.2554","article-title":"Vaccine development for an imminent pandemic: why we should worry, what we must do","volume":"2","author":"Fedson","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2023.08.009_b0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biologicals.2009.02.014","article-title":"FluBlok, a next generation influenza vaccine manufactured in insect cells","volume":"37","author":"Cox","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2023.08.009_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1279765","article-title":"Panblok-H1+advax H1N1\/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine","volume":"13","author":"Honda-Okubo","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.08.009_b0065","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2013.08.064","article-title":"Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5\/Indonesia\/05\/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant","volume":"31","author":"Treanor","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.009_b0070","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.vaccine.2016.12.053","article-title":"Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial","volume":"35","author":"Treanor","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.009_b0075","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1016\/j.vaccine.2018.06.007","article-title":"Protection by universal influenza vaccine is mediated by memory CD4 T cells","volume":"36","author":"Valkenburg","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.009_b0080","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/irv.12466","article-title":"Lineage-specific epitope profiles for HPAI H5 pre-pandemic vaccine selection and evaluation","volume":"11","author":"Qiu","year":"2017","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2023.08.009_b0085","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.009_b0090","doi-asserted-by":"crossref","first-page":"1105655","DOI":"10.3389\/fimmu.2023.1105655","article-title":"Review: Current trends, challenges, and success stories in adjuvant research","volume":"14","author":"Singleton","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.08.009_b0095","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1016\/j.vaccine.2012.06.021","article-title":"Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses","volume":"30","author":"Honda-Okubo","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.009_b0100","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1016\/j.vaccine.2011.06.078","article-title":"Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets","volume":"29","author":"Layton","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.009_b0105","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","article-title":"Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant","volume":"30","author":"Gordon","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.009_b0110","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"issue":"504\u201313","key":"10.1016\/j.vaccine.2023.08.009_b0115","first-page":"e16","article-title":"Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy","volume":"144","author":"Heddle","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2023.08.009_b0120","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cmi.2022.04.004","article-title":"Safety and immunogenicity of SpikoGen(R), an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations","volume":"28","author":"Tabarsi","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2023.08.009_b0125","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imm.13540","article-title":"Immunogenicity and safety of SpikoGen(R), an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial","volume":"167","author":"Tabarsi","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2023.08.009_b0130","doi-asserted-by":"crossref","DOI":"10.1002\/0471142956.cy0911s27","article-title":"Flow cytometric analysis of cell division by dye dilution","author":"Lyons","year":"2004","journal-title":"Curr Protoc Cytom"},{"key":"10.1016\/j.vaccine.2023.08.009_b0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcv.2019.08.009","article-title":"Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination","volume":"119","author":"Jansen","year":"2019","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2023.08.009_b0140","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.08.009_b0145","doi-asserted-by":"crossref","first-page":"E2514","DOI":"10.1073\/pnas.1402766111","article-title":"Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection","volume":"111","author":"Mallajosyula","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2023.08.009_b0150","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jviromet.2013.08.022","article-title":"The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response","volume":"194","author":"Lee","year":"2013","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2023.08.009_b0155","doi-asserted-by":"crossref","first-page":"9198","DOI":"10.1038\/s41598-022-12727-y","article-title":"Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants","volume":"12","author":"Hernandez-Davies","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.08.009_b0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.intimp.2012.10.019","article-title":"TLR agonists are highly effective at eliciting functional memory CTLs of effector memory phenotype in peptide immunization","volume":"15","author":"Smyth","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2023.08.009_b0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41541-017-0036-2","article-title":"Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines","volume":"2","author":"Sutton","year":"2017","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.08.009_b0170","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3389\/fmicb.2019.02031","article-title":"Soluble recombinant hemagglutinin protein of H1N1pdm09 influenza virus elicits cross-protection against a lethal H5N1 challenge in mice","volume":"10","author":"Yamada","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2023.08.009_b0175","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1099\/vir.0.019190-0","article-title":"An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses","volume":"91","author":"Lobigs","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2023.08.009_b0180","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.08.009_b0185","article-title":"An advax-adjuvanted inactivated cell-culture derived Japanese encephalitis vaccine induces broadly neutralising anti-flavivirus antibodies, robust cellular immunity and provides single dose protection","volume":"9","author":"Komiya","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.009_b0190","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ebiom.2016.11.015","article-title":"Advax, a delta inulin microparticle, potentiates in-built adjuvant property of co-administered vaccines","volume":"15","author":"Hayashi","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2023.08.009_b0195","doi-asserted-by":"crossref","first-page":"e0132003","DOI":"10.1371\/journal.pone.0132003","article-title":"Delta inulin adjuvant enhances plasmablast generation, expression of activation-induced cytidine deaminase and B-cell affinity maturation in human subjects receiving seasonal influenza vaccine","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.08.009_b0200","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-1-4939-3387-7_14","article-title":"Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant","volume":"1403","author":"McPherson","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2023.08.009_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/v11030212","article-title":"Efficacy of an adjuvanted middle east respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas","volume":"11","author":"Adney","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.08.009_b0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2022.09.001","article-title":"Evaluating the efficacy and safety of SpikoGen(R), an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tabarsi","year":"2023","journal-title":"Clin Microbiol Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:32:32Z","timestamp":1778679152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23009416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0264410X23009416"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}